James George Chopas
CIK 1836430 · VP/Chief Accounting Officer · last filed 2026-05-14
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$0
Companies
2
Total Filings
49
Lifetime Open-Market Net
-$382.7K
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Apellis Pharmaceuticals, Inc. (APLS) Delisted | VP/Chief Accounting Officer | 8,075 | $41.03 | $331.3K | -$374.9K | 30 | 2026-05-14 |
| Radius Health, Inc. (RDUS) Delisted | Principal Finance Accounting | 6,701 | $30.00 | $201.0K | -$7.7K | 3 | 2021-03-09 |
Recent Filings · Page 4 of 5
49 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-01-17 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Mixed | +7,448 | -$57.7K | EDGAR |
| 2024-01-16 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Notice (144) | −864 | -$57.7K | EDGAR |
| 2023-10-24 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Sell (S) | −132 | -$6.1K | EDGAR |
| 2023-10-23 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Notice (144) | −132 | -$6.1K | EDGAR |
| 2023-09-18 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Grant (A) | +2,500 | $0 | EDGAR |
| 2023-09-01 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Sell (S) | −551 | -$22.7K | EDGAR |
| 2023-08-31 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Notice (144) | −551 | -$22.7K | EDGAR |
| 2023-02-22 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Mixed | +3,710 | -$19.5K | EDGAR |
| 2023-01-24 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Tax (F) | −919 | -$47.8K | EDGAR |
| 2023-01-17 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Grant (A) | +9,621 | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.